Canaccord stopped a Kaufempfehlung and Kursziel for Tenaya-Aktien fest from Investing.com

The service calculates Canaccord Genuity as the Buyer for the shares of Tenaya Therapeutics Inc (NASDAQ:TNYA) with a price of 16.00 US dollars. The analytics house has conducted the clinical data verification for the Gene Therapy Program TN-201 as one of the best ways to do this.

Tenaya Therapeutics at one point sought results from the Phase 1b trial of TN-201, which could provide gene therapy candidates for hypertrophic cardiomyopathy (HCM). These dates, which were for the fourth quarter of 2024, marked the world of Unternehmens in the clinical development phase.

TN-201, one of the AAV9-based gene therapies, is one of the forms of HCM that is treated – an analysis, which is carried out during a treatment of the herzmuskels. The treatment of data can take place for the first time on the treatment and the certainty of the therapy in a small patient group.

Canaccord Genuity has conducted an analysis of the TN-201 programs based on the most important data points, increasing the focus of the external connections. The Tenaya Therapeutics is critical, has a positive impact on the company and has discovered a number of possible sources of active activity.

The strength of the outsiders and the protected datenveröffentlichung became Tenaya’s position on the market festive, where the bekräftige Kaufempfehlung of Canaccord Genuity das Vertrauen in the Wachstumspotenzial des Unternehmens broader mirrors.

In others, the following articles from Tenaya Therapeutics are Reihe von Veränderungen verzeichnet. The biotechnology companies can make a greater contribution to the development of their businesses and the development of Karah Parschauer as a Class II director, and the introduction of a new 2024 Inducement Equity Incentive Plan. The plan concerns the proceeds of 1,200,000 stock brokers through the various Equity Awards, with these new shares or as part of Fusions and shares.

Darüber said he took over the company Abgang von Leone Patterson, the Chief Financial and Business Officer, was such a new CFO ever. Significant matters would be messages in Tenaya’s Forschungsleitungsteam, with Kathy Ivey’s communication to Senior Vice President, Research, and Timothy Hoey’s mountain corridor in a deliberated Rolle.

Analysts from William Blair and Canaccord Genuity looked at Tenaya in their research, which viewed the Beobachting with an Outperform-Rating and showed a Kauffehlung, all with a new course. Positive research has been done on the unternehmens gene therapy candidates, TN-201 and TN-401, here.

Zuletzt HC Wainwright a Kaufempfehlung for Tenaya was the Optimismus over the Fortschritt of the Unternehmens at the Entwicklung of Treatments for hypertrophic Cardiomyopathy more broadly mirrored, with a focus on the frozen data from the MyPeak-1-Study. These young studies are being continued in Tenaya Therapeutics’ treatment.

InvestingPro Insights

After all, Tenaya Therapeutics Inc (NASDAQ:TNYA) has critical TN-201-Datenveröffentlichung nähert, more InvestingPro-Daten sisterätzlichen Kontext for Investors. The market capitalization of the Unternehmens amounted to 152.26 million US dollars and was reflected more broadly by the Entwicklungsstatus. Trotz des positives Ausblicks von Canaccord Genuity said InvestingPro-Tipps, that Tenaya “schnell Bargeld verrennt” and “in the letzten zölf Monaten not profitable” war, with a bereinigten operator Ergebnis of -126,95 Millionen US-Dollar for that letzten zölf Monate until Q2 2024.

This financial knowledge relates to the clinical clinical data for the TN-201. An incorrect representation of the advice of external parties is important when one considers that the company currently trades 27.53% of the 52 living hours in the world. InvestingPro-Tipps we said that there were “3 analysts in the earnings forecast for the coming period after good preparation” were an optimal optimistic view of the financial prospects.

For investors, the potential investment opportunities of Tenaya are worth considering, with InvestingPro 11 sister tips for TNYA offers, which provide a comprehensive analysis of financial prosperity and market position of our internal economies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.